1466 related articles for article (PubMed ID: 28196815)
1. Major Bleeding Complications and Persistence With Oral Anticoagulation in Non-Valvular Atrial Fibrillation: Contemporary Findings in Real-Life Danish Patients.
Lamberts M; Staerk L; Olesen JB; Fosbøl EL; Hansen ML; Harboe L; Lefevre C; Evans D; Gislason GH
J Am Heart Assoc; 2017 Feb; 6(2):. PubMed ID: 28196815
[TBL] [Abstract][Full Text] [Related]
2. Effectiveness and safety of reduced dose non-vitamin K antagonist oral anticoagulants and warfarin in patients with atrial fibrillation: propensity weighted nationwide cohort study.
Nielsen PB; Skjøth F; Søgaard M; Kjældgaard JN; Lip GY; Larsen TB
BMJ; 2017 Feb; 356():j510. PubMed ID: 28188243
[No Abstract] [Full Text] [Related]
3. Real-World Setting Comparison of Nonvitamin-K Antagonist Oral Anticoagulants Versus Vitamin-K Antagonists for Stroke Prevention in Atrial Fibrillation: A Systematic Review and Meta-Analysis.
Ntaios G; Papavasileiou V; Makaritsis K; Vemmos K; Michel P; Lip GYH
Stroke; 2017 Sep; 48(9):2494-2503. PubMed ID: 28716982
[TBL] [Abstract][Full Text] [Related]
4. Effectiveness and Safety of Dabigatran, Rivaroxaban, and Apixaban Versus Warfarin in Nonvalvular Atrial Fibrillation.
Yao X; Abraham NS; Sangaralingham LR; Bellolio MF; McBane RD; Shah ND; Noseworthy PA
J Am Heart Assoc; 2016 Jun; 5(6):. PubMed ID: 27412905
[TBL] [Abstract][Full Text] [Related]
5. Real-world comparison of major bleeding risk among non-valvular atrial fibrillation patients initiated on apixaban, dabigatran, rivaroxaban, or warfarin. A propensity score matched analysis.
Lip GY; Keshishian A; Kamble S; Pan X; Mardekian J; Horblyuk R; Hamilton M
Thromb Haemost; 2016 Oct; 116(5):975-986. PubMed ID: 27538358
[TBL] [Abstract][Full Text] [Related]
6. Comparative effectiveness and safety of non-vitamin K antagonist oral anticoagulants and warfarin in patients with atrial fibrillation: propensity weighted nationwide cohort study.
Larsen TB; Skjøth F; Nielsen PB; Kjældgaard JN; Lip GY
BMJ; 2016 Jun; 353():i3189. PubMed ID: 27312796
[TBL] [Abstract][Full Text] [Related]
7. Three-month risk-benefit profile of anticoagulation after stroke with atrial fibrillation: The SAMURAI-Nonvalvular Atrial Fibrillation (NVAF) study.
Arihiro S; Todo K; Koga M; Furui E; Kinoshita N; Kimura K; Yamagami H; Terasaki T; Yoshimura S; Shiokawa Y; Kamiyama K; Takizawa S; Okuda S; Okada Y; Nagakane Y; Kameda T; Hasegawa Y; Shibuya S; Ito Y; Nakashima T; Takamatsu K; Nishiyama K; Matsuki T; Homma K; Takasugi J; Tokunaga K; Sato S; Kario K; Kitazono T; Toyoda K;
Int J Stroke; 2016 Jul; 11(5):565-74. PubMed ID: 26927811
[TBL] [Abstract][Full Text] [Related]
8. Comparative Stroke, Bleeding, and Mortality Risks in Older Medicare Patients Treated with Oral Anticoagulants for Nonvalvular Atrial Fibrillation.
Graham DJ; Baro E; Zhang R; Liao J; Wernecke M; Reichman ME; Hu M; Illoh O; Wei Y; Goulding MR; Chillarige Y; Southworth MR; MaCurdy TE; Kelman JA
Am J Med; 2019 May; 132(5):596-604.e11. PubMed ID: 30639551
[TBL] [Abstract][Full Text] [Related]
9. A nationwide registry study to compare bleeding rates in patients with atrial fibrillation being prescribed oral anticoagulants.
Halvorsen S; Ghanima W; Fride Tvete I; Hoxmark C; Falck P; Solli O; Jonasson C
Eur Heart J Cardiovasc Pharmacother; 2017 Jan; 3(1):28-36. PubMed ID: 27680880
[TBL] [Abstract][Full Text] [Related]
10. Effectiveness and Safety of Apixaban, Dabigatran, and Rivaroxaban Versus Warfarin in Frail Patients With Nonvalvular Atrial Fibrillation.
Martinez BK; Sood NA; Bunz TJ; Coleman CI
J Am Heart Assoc; 2018 Apr; 7(8):. PubMed ID: 29654196
[TBL] [Abstract][Full Text] [Related]
11. Real-world comparison of bleeding risks among non-valvular atrial fibrillation patients prescribed apixaban, dabigatran, or rivaroxaban.
Tepper PG; Mardekian J; Masseria C; Phatak H; Kamble S; Abdulsattar Y; Petkun W; Lip GYH
PLoS One; 2018; 13(11):e0205989. PubMed ID: 30383768
[TBL] [Abstract][Full Text] [Related]
12. Effectiveness and safety of non-vitamin K antagonist oral anticoagulants and warfarin in atrial fibrillation: a Scandinavian population-based cohort study.
Halvorsen S; Johnsen SP; Madsen M; Linder M; Sulo G; Ghanima W; Gislason G; Hohnloser SH; Jenkins A; Al-Khalili F; Tell GS; Ehrenstein V
Eur Heart J Qual Care Clin Outcomes; 2022 Aug; 8(5):577-587. PubMed ID: 34244745
[TBL] [Abstract][Full Text] [Related]
13. Non-vitamin K antagonist oral anticoagulation agents in anticoagulant naïve atrial fibrillation patients: Danish nationwide descriptive data 2011-2013.
Olesen JB; Sørensen R; Hansen ML; Lamberts M; Weeke P; Mikkelsen AP; Køber L; Gislason GH; Torp-Pedersen C; Fosbøl EL
Europace; 2015 Feb; 17(2):187-93. PubMed ID: 25236181
[TBL] [Abstract][Full Text] [Related]
14. Bleeding risk of apixaban, dabigatran, and low-dose rivaroxaban compared with warfarin in Japanese patients with non-valvular atrial fibrillation: a propensity matched analysis of administrative claims data.
Kohsaka S; Murata T; Izumi N; Katada J; Wang F; Terayama Y
Curr Med Res Opin; 2017 Nov; 33(11):1955-1963. PubMed ID: 28857611
[TBL] [Abstract][Full Text] [Related]
15. Major bleeding risk among non-valvular atrial fibrillation patients initiated on apixaban, dabigatran, rivaroxaban or warfarin: a "real-world" observational study in the United States.
Lip GY; Pan X; Kamble S; Kawabata H; Mardekian J; Masseria C; Bruno A; Phatak H
Int J Clin Pract; 2016 Sep; 70(9):752-63. PubMed ID: 27550177
[TBL] [Abstract][Full Text] [Related]
16. Effectiveness and Safety of Apixaban, Dabigatran, and Rivaroxaban Versus Warfarin in Patients With Nonvalvular Atrial Fibrillation and Previous Stroke or Transient Ischemic Attack.
Coleman CI; Peacock WF; Bunz TJ; Alberts MJ
Stroke; 2017 Aug; 48(8):2142-2149. PubMed ID: 28655814
[TBL] [Abstract][Full Text] [Related]
17. Major Bleeding Risk During Anticoagulation with Warfarin, Dabigatran, Apixaban, or Rivaroxaban in Patients with Nonvalvular Atrial Fibrillation.
Adeboyeje G; Sylwestrzak G; Barron JJ; White J; Rosenberg A; Abarca J; Crawford G; Redberg R
J Manag Care Spec Pharm; 2017 Sep; 23(9):968-978. PubMed ID: 28854073
[TBL] [Abstract][Full Text] [Related]
18. Drug Utilization Pattern of Oral Anticoagulants in Patients with Atrial Fibrillation: A Nationwide Population-Based Study in Korea.
Lee MY; Han S; Bang OY; On YK; Jang SW; Han S; Ryu J; Park YJ; Kang S; Suh HS; Kim YH
Adv Ther; 2022 Jul; 39(7):3112-3130. PubMed ID: 35524839
[TBL] [Abstract][Full Text] [Related]
19. Comparative risk of major bleeding with new oral anticoagulants (NOACs) and phenprocoumon in patients with atrial fibrillation: a post-marketing surveillance study.
Hohnloser SH; Basic E; Nabauer M
Clin Res Cardiol; 2017 Aug; 106(8):618-628. PubMed ID: 28293797
[TBL] [Abstract][Full Text] [Related]
20. The risk of stroke/systemic embolism and major bleeding in Asian patients with non-valvular atrial fibrillation treated with non-vitamin K oral anticoagulants compared to warfarin: Results from a real-world data analysis.
Bang OY; On YK; Lee MY; Jang SW; Han S; Han S; Won MM; Park YJ; Lee JM; Choi HY; Kang S; Suh HS; Kim YH
PLoS One; 2020; 15(11):e0242922. PubMed ID: 33253294
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]